Cibc World Market Inc. Decreases Position in Tenet Healthcare Corporation $THC

Cibc World Market Inc. decreased its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 9.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,948 shares of the company’s stock after selling 2,598 shares during the quarter. Cibc World Market Inc.’s holdings in Tenet Healthcare were worth $4,862,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. ProShare Advisors LLC increased its holdings in shares of Tenet Healthcare by 1.7% in the 2nd quarter. ProShare Advisors LLC now owns 4,118 shares of the company’s stock worth $725,000 after purchasing an additional 67 shares in the last quarter. Quadcap Wealth Management LLC boosted its position in shares of Tenet Healthcare by 1.7% during the second quarter. Quadcap Wealth Management LLC now owns 4,099 shares of the company’s stock valued at $721,000 after buying an additional 69 shares during the last quarter. Andina Capital Management LLC raised its position in Tenet Healthcare by 2.1% in the 3rd quarter. Andina Capital Management LLC now owns 3,360 shares of the company’s stock worth $682,000 after buying an additional 69 shares during the last quarter. Assetmark Inc. lifted its stake in Tenet Healthcare by 0.9% during the 2nd quarter. Assetmark Inc. now owns 8,709 shares of the company’s stock valued at $1,533,000 after acquiring an additional 76 shares during the period. Finally, MGO One Seven LLC grew its stake in shares of Tenet Healthcare by 3.8% in the third quarter. MGO One Seven LLC now owns 2,231 shares of the company’s stock worth $453,000 after acquiring an additional 82 shares during the period. 95.44% of the stock is owned by institutional investors.

Tenet Healthcare Stock Down 0.6%

THC stock opened at $230.90 on Friday. The business’s 50-day moving average price is $198.82 and its 200-day moving average price is $194.95. The stock has a market cap of $20.29 billion, a P/E ratio of 14.91, a PEG ratio of 0.96 and a beta of 1.44. The company has a quick ratio of 1.64, a current ratio of 1.76 and a debt-to-equity ratio of 2.18. Tenet Healthcare Corporation has a twelve month low of $109.82 and a twelve month high of $235.77.

Tenet Healthcare (NYSE:THC) last released its earnings results on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, topping analysts’ consensus estimates of $4.08 by $0.62. The company had revenue of $5.53 billion for the quarter, compared to analysts’ expectations of $5.47 billion. Tenet Healthcare had a net margin of 6.60% and a return on equity of 26.33%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $3.44 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. On average, equities research analysts forecast that Tenet Healthcare Corporation will post 12.24 EPS for the current year.

Insider Transactions at Tenet Healthcare

In other news, Director Nadja West sold 2,178 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $197.47, for a total value of $430,089.66. Following the completion of the transaction, the director owned 28,480 shares of the company’s stock, valued at $5,623,945.60. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.81% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on THC. Wall Street Zen upgraded shares of Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Barclays raised their price target on Tenet Healthcare from $240.00 to $257.00 and gave the stock an “overweight” rating in a research note on Friday. UBS Group increased their target price on Tenet Healthcare from $260.00 to $288.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen restated a “buy” rating on shares of Tenet Healthcare in a research note on Thursday. Finally, Royal Bank Of Canada increased their price objective on shares of Tenet Healthcare from $253.00 to $277.00 and gave the stock an “outperform” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $242.82.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.